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Introduction: Prostate cancer is one of the most common cancers and the 
second major cause of mortality in men. Different researches have shown that 
the overexpression of a gene called twist1 leads to initiation of metastasis 
process in this cancer. TWIST1 protein triggers this process through 
stimulating the transition pathway of cells from epithelial to mesenchymal 
tissue. 
Materials and Methods: In this study, four oligonucleotides of antisense 
RNA have been designed for twist1 gene, and its anti-metastatic effect was 
examined in two cell lines PC3 and LNCaP. The antisense oligonucleotides 
(ASOs) were designed as single strands with a length of 20 nucleotides and 
chosen from ASOs suggested by Soligo program. The ASOs were synthesized 
in phosphorothioated form. MTT assay was used for evaluating the ASOs 
cytotoxicity effect on PC3 and LNCaP cell lines. The cell lines were 
transfected with 500 nmol of antisense oligonucleotides using cationic polymer 
turbofect and incubated for 48 hours, and then, their invasive ability were 
measured by CytoSelect™ Cell Invasion Assay Kit. 
Results: The anti-invasive effect of ASOs in LNCaP and PC3 had a 
significant difference. This effect was more significant in LNCaP cell line as 
compared to PC3. The most anti- invasive effect was observed in LNCaP cell 
line (50%). 
Conclusion: According to the results, Antisense oligonucleotides were 
effective in decreasing the invasion ability of two cell lines PC3 and LNCaP 
and therfore can be considered as a good candidate for preventing the prostate 
cancer metastasis. 
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     Prostate cancer is the most common 
cancer and the fifth cause of cancer-induced 
mortality among men in developed 
countries [1, 2]. The main cause of 
mortality induced by prostate cancer is its 
metastasis to other tissues of the body. 
More than any other solid tumor, prostate 
cancer metastasizes to the bone tissue. 
Around 65-75% of men with advanced 
prostate cancer suffer from bone metastasis 
[3]. One of the genes that initiates 
metastasis is twist1 gene, which codes a 
transcription factor with a basic helix-loop-
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helix structure [4]. Normally, the maximum 
expression of this gene occurs in the 
placenta and during embryonic 
development, when the cells move and 
differentiate, whereby different tissues and 
organs are formed [5]. After the birth and in 
adulthood, this gene can act as an oncogene 
[6]. The overexpression of this gene in 
cancer cells such as prostate, breast, lungs, 
uterus, skin, stomach, melanoma, 
osteosarcoma, rhabdomyosarcomas, and 
other tumors confirms this issue [7-10]. 
Twist1 suppresses the expression of E-
cadherin and increases Epithelial 
Mesenchymal Transition (EMT) which 
occurs in the primary stage of metastasis, 
and is a process whereby the epithelial cells 
lose their polarity and adhesion capability 
[11]. Unlike most solid tumors, prostate 
cancer has usually a poor response to 
chemotherapeutic agents. Thus, developing 
new drugs for the treatment of prostate 
cancer and preventing initiation of 
metastasis are inevitable [11]. When the 
overexpression of a special gene is known 
as a cause of disease progress, a single-
strand nucleic acid (DNA, RNA, or its 
chemical analog) can be synthesized, 
forming an RNA/DNA double strand, 
causing diminished level of mRNA and 
targeting protein [7, 8]. One of the 
inhibitors for gene expression which has 
attracted researchers’ attention is antisense 
oligonucleotides. An antisense 
oligonucleotide is a short single strand 
deoxyribonucleic acid with typical length of 
20 nucleotides, with complementary 
sequence of target gene’s mRNA [12, 13]. 
Antisense drugs become hybridized with a 
special mRNA and can prevent its 
translation to protein. Indeed, they can 
cause inhibition of transference of genetic 
information from DNA to the protein [14, 
15]. The most important advantage of 
antisense drugs is that these molecules have 
the maximum effect on the target cell, while 
creating the minimum side effects compared 
to other drugs [16]. Numerous antisense 
drugs are in different stages of clinical 
experiments, and some of them have been 
approved by the Food and Drug 
Organization of the United States [17, 18]. 
Other advantages of RNA antisense drugs 
are their easy design and formulation 
approach in comparison to chemical drugs 
[13]. In this research, four antisense 
oligonucleotides was designed for the 
mRNA of twist1 gene, and their cytotoxicity 
and inhibitory effect were evaluated on 
invasive ability of two cell lines of prostate 
cancer, PC3 and LNCaP.  
 
2. Materials and Methods 
2.1. Antisense oligonucleotides design 
     Since antisense nucleotide strands are 
rapidly attacked by all types of nucleases, 
the designed oligonucleotides were 
synthesized in phosphorothioate form. This 
is because a phosphorothioated ASO not 
only enhances nuclease resistance, but also 
is better absorbed by the surface proteins of 
cells [19]. To design the antisense 
oligonucleotides, the sequence of mRNA of 
twist1 gene with the identification number 
of NM-000474.4 was accessed through 
NCBI database with the address of 
https://www.ncbi.nlm.nih.gov. Then, it was 
entered in sfold Web server, which was 
created by Y Ding in 2004 for rational 
design of nucleic acids with the address of 
sfold.wadsworth.org, where the requested 
information was recorded in the soligo part. 
Different antisense oligonucleotides were 
proposed by the mentioned server. Four 
different oligonucleotides were chosen 
considering different factors such as ΔG of 
the hybridization reaction, GC content, and 
presence or absence of special motifs. Next, 
the similarity of oligonucleotide sequences 
with other genes of human genome was 
compared by online BLAST to ensure that 
they will only attach to their particular 
sequence in twist1 gene. Eventually, the 
mentioned oligonucleotides, TW6, TW5, 
TW4 and TW3, were synthesized by SBS 
Genetech Co. Ltd in phosphorothioated 
form (Table 1). 
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Table 1. Antisense Oligonucleotide sequences, GC% 
and ΔG 
Name Sequence (5´-3´) GC% ΔG 
TW3 CGTCCTGCATCATCTCTCGA 55% -9.8 
TW4 TGGCTCTTCCTCGCTGTTGC 60% -8.8 
TW5 ACGTCCTGCATCATCTCTCG 55% -10.3 
TW6 CTGGCTCTTCCTCGCTGTTG 60% -9.1 
 
 
2.2. Tumor cell lines, culture and 
transfection 
     The human prostate cancer cell lines 
PC3 (grade IV, adenocarcinoma and 
derived from metastatic bone) and LNCap 
(carcinoma and derived from metastatic left 
supraclavicular lymph node) were provided 
from Avicenna Research Institute (Fig.1). 
The tumor cell culture media were removed 
from the culture flasks. Then the cells were 
washed two times by adding of 2-3ml of 
phosphate‑ buffered saline (PBS (1x); 
Inoclon). Subsequently, an equal volume of 
0.25% Trypsin-EDTA (1-2ml) (Inoclon) 
was added and the cells were incubated at 
37°C in humidified atmosphere containing 
5% CO2 for approximately two minutes. 
The cells were observed under the 
microscope. When ≥ 90% of the cells were 
detached, 3-5ml of RPMI- 1640 (Bio-Idea) 
with 10% fetal bovine serum (FBS. Gibco) 
was added for inactivation of trypsin. 
Detached cells were transferred to a 15-mL 
tube and centrifuged at 1200rpm at 25°C for 
5 minutes. The cell pellets were re-
suspended in a complete culture medium 
(10% FBS and 1% penicillin/streptomycin) 
(Inoclon). The suspension was gently 
dispersed by pipetting and transferred into 
new flasks. Finally, tumor cells were 
incubated at 37°C in humidified atmosphere 
containing 5% CO2. There are currently 
several commercial transporter reagents for 
DNA and protein into cells, which their 
formulation is based on lipid, polymer, or 
peptide that facilitate their cellular uptake. 
Nucleic acids cannot enter into the cells 
without the aid of transfection reagents. The 
transporter reagent used in this study was 
TurboFect (Thermo Fisher Scientific) that is 
a cationic polymer, has high cellular 
absorption and enters the cell via 
micropinocytosis. Adding serum to the 
culture medium can reduce the absorption 




Figure1. The human prostate cancer cell lines PC3 (left) and LNCap (right) 
 
2.3. MTT assay 
     Cell toxicity of ASOs in LNCaP and PC-
3 cell lines was determined by using the 
colorimetric MTT cell viability assay. 
About 8000 cells were seeded in each well 
of 96- well plate and incubated overnight. 
The next day, the cells were starved for 2-3 
hours and treated with different amounts of 
each ASOs (0, 62.5, 125, 250, 500 and 1000 
nmol), TurboFect (0, 0.625, 1.25, 2.5, 5 and 
10 μl were used respectively for antisense 
oligonucleotides concentrations mentioned 
above) and serum-free RPMI 1640. Before 
transfection, Turbofect and ASOs were 
incubated for 20 min at room temperature. 
Also according to TurbFect’s toxic effect on 
cells, the cell lines were treated with same 
concentrations of TurboFect without ASOs. 
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Subsequently, the old media was replaced 
with new culture media with 10% FBS. 
After 48 hours incubation at 37°C in 5% 
CO2 atmosphere, 200 μl of 0.5 mg/ml MTT 
(Merk) was added to each well and 
incubated at 37°C for 4 hours. Then, media 
was discarded and 100 μl of DMSO 
(Inoclon) added into wells carefully. The 
plate was covered with tinfoil and cells 
were agitated on orbital shaker for 1 hour. 
Finally, absorbance measured at 560 nm 
with ELISA Reader (BioTek). 
Experiments were repeated 3 times. 
Data was evaluated with Graph Pad Prism 
6.  
 
2.4. Cell Invasion Assay 
     Cell invasion assay was performed using 
the CytoSelect™ Cell Invasion Assay Kit, 
containing polycarbonate membrane inserts 
in a 24-well plate. Inserts had 8 µm pore 
size membranes. The invasion chamber 
plate was warmed up at 25°C for 10 
minutes. By adding 300 μl of serum-free 
media to the inner compartment basement 
membrane layer of the cell culture, inserts 
were rehydrated and incubated at 25°C for 1 
hour. Then, rehydration medium was 
removed from the inserts, carefully. A cell 
suspension containing 75  cells/ml was 
prepared in FBS free medium (300 μl of this 
suspension was added to the inside of the 
inserts and starved for 1 hour). Cells were 
treated with 500 nmol of each antisense 
oligonucleotide. Then, 500 μL of media 
containing 10% fetal bovine serum added to 
the lower well of the invasion plate. After 
48 hours incubation at 37°C in 5% CO2 
atmosphere, the media from the inside of 
the insert was discarded. Non‐ invasive 
cells were removed from the upper surface 
of the membrane by swab. Inserts were 
stained with 400 μL of cell stain solution 
and incubated for 10 minutes at 25°C. The 
stained inserts were washed with water, air 
dried and stained with adding 200 μL of 
extraction solution per wells, then incubated 
10 minutes on a shaker. 100 μL of each 
sample was transferred to a 96-well plate 
and OD560 was measured with ELISA 
Reader (BioTek).  
Experiments were repeated 3 times. 




     According to the present study, 
cytotoxicity of different concentrations of 
antisense oligonucleotides (0, 62.5, 125, 
250, 500 and 1000 nmol), and carrier 
molecule, TurboFect, (0, 0.625, 1.25, 2.5, 5 
and 10 μl respectively added for different 
concentrations of antisense 
oligonucleotides) was evaluated by MTT 
assay. As shown in Fig. 2, at concentration 
of 1000 nmol of antisense oligonucleotides 
(TW3, TW4, TW5, TW6) on PC3 cell line, 
34%, 23%, 31% and 59% of the cells were 
dead respectively, 14% of which were due 
to the Turbofect effect. As observed in Fig. 
3, at concentration of 1000 nmol of the 
same antisense oligonucleotides on LNCaP 
cell line, 28%, 30%, 37% and 33% of cells 
were dead, 11% of which were due to the 
Turbofect effect. Therefore, 500 nmol of the 
antisense oligonucleotides was select for 
invasive assay without interference of 
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Figure 2. Determination of the toxicity of antisense oligonucleotides (TW3, TW4, TW5 and TW6) & TurboFect on PC3 
cell line by MTT assay 
PC3 cells (100 μl) were plated in a 96well plate and cultured with various concentrations of each antisense 
oligonucleotide (0, 62.5, 125, 250, 500 and 1000 nmol).  For antisense oligonucleotide delivery into cells, TurboFect was 
used in 0, 0.625, 1.25, 2.5, 5 and 10 μl respectively. After 48 h, the cells were treated with MTT for 4 h at 37˚C, and 
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Figure 3. Estimation of antisense oligonucleotides (TW3, TW4, TW5, and TW6) & TurboFect toxicity on LNCaP cell 
line by MTT assay 
LNCaP cells (100 μl) were plated in a 96well plate and cultured with various concentrations of antisense oligonucleotides 
(0, 62.5, 125, 250, 500 and 1000 nmol).  For antisense oligonucleotide delivery into cells, TurboFect was used in 0, 
0.625, 1.25, 2.5, 5 and 10 μl respectively. After 48 h, the cells were treated with MTT for 4 h at 37˚C, and absorbance 
was measured at 560 nm. Data are presented as mean ± SEM (n=3). (****P < 0.0001 different from the control). 
 
Subsequently, the concentration of 500 
nmol of antisense oligonucleotides was used 
to examine anti-invasive effect of them on 
PC3 and LNCaP cell lines using Cell 
Invasion Assay Kit. The invasive potential 
of PC3 and LNCap cell lines transfected 
with the 500 nm of antisense 
oligonucleotides (TW3, TW4, TW5, TW6 
and TurboFect alone) was examined. As 
shown in Fig. 4, TurboFect, TW5, TW3, 
TW6 and TW4 reduced LNCaP cells 
invasion ability 8, 16, 58, 10 and 35% 
respectively in comparison to control cells. 
These results were 4, 15, 30, 28 and 27% on 
PC3 cells (data was shown in Fig. 5). The 
antisense oligonucleotide, TW3, had the 
main anti- invasive effect on LNCap cells. 
However this oligonucleotide showed 
similar effect with TW6 and TW4 on PC3 














































































Figure4. Effects of Antisense oligonucleotides (TW3, TW4, TW5 and TW6) on LNCaP cell invasion. 
 LNCaP cells were seeded at 75  cells/well and allowed to invade toward 10% FBS for 48 hours in the presence and 
absence of antisense oligonucleotides. Invasive cells on the bottom of the invasion membrane were stained and quantified 
at OD 560 nm. Data are presented as mean ± SEM (n=3). (*P < 0.05, ***P < 0.001 and ****P < 0.0001 different from 
the control).  
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Figure 5. Effects of Antisense oligonucleotides (TW3, TW4, TW5 and TW6) on PC3 cell invasion.  
PC3 cells were seeded at 75  cells/well and allowed to invade toward 10% FBS for 48 hours in the presence and 
absence of antisense oligonucleotides. Invasive cells on the bottom of the invasion membrane were stained and quantified 
at OD 560 nm. Data are presented as mean ± SEM (n=3). (**P<0.01 and ****P<0.0001 different from the control).  
 
4. Discussion 
     Antisense technology is used for 
different therapeutic and non-therapeutic 
goals nowadays. There are several reports 
about different antisense molecules used 
against prostate cancer however many of 
them are about anti-apoptotic effect of 
antisense molecules and not anti-invasive 
effect of them.  In 2001, different antisense 
oligonucleotide drugs have been used to 
control various cancers by Chi et al.  For 
example, the combination of Genasense 
antisense oligonucleotide designed against 
bcl-2 mRNA and mitoxantrone was used for 
the treatment of hormone refractory prostate 
cancer in phase 1 clinical trial study. There 
was a synergistic effect between antisense 
oligonucleotides and mitoxantrone in those 
patients for increasing of chemo sensitivity 
of prostate cancer cells [21]. Another case 
was the antisense oligonucleotide therapy 
targeting clusterin gene which led to 
apoptosis in prostate cancer cells [22]. 
Moreover, there was a study about the role 
of STAT3 abnormal signaling in 
Hepatocellular carcinoma (HCC). The 
results showed inhibition of vascular 
endothelial growth factor expression by 
antisense oligonucleotide targeting STAT3 
reduced cell proliferation and migratory 
potential of HCCs [23]. In 2002, Khatib and 
colleagues reported that down regulating the 
expression of hepatic endothelial E-Selectin 
gene by C-raf antisense oligonucleotide can 
reduce the colorectal carcinoma liver 
metastasis by 86% [24]. Another 
experiment was done by Margheri, 
representing the significant decrease in 
urokinase receptor signaling pathway in 
prostate cancer bone metastasis mouse 
model through using antisense 
oligonucleotides [25].  
The results of the present study 
demonstrated that twist1 antisense 
oligonucleotides enforce an anti-invasive 
effect on both early and advanced 
metastatic prostate cancer cells. Treatment 
of prostate cancer cells (LNCaP & PC3) 
with 500nmol of different antisense 
oligonucleotides leads to different 
inhibitory effects on their invasion ability. 
The maximum effect was related to TW3 
antisense oligonucleotide with 50 and 26 % 
anti-invasive effect on LNCaP and PC3 cell 
lines, respectively. These results manifest 
that using the appropriate antisense drug for 
twist1 gene can prevent metastatic process 
in cancerous cells effectively. Particularly, 
combination of two or more effective 
antisense oligonucleotides against genes 
have an important effect in metastasis of 
cancerous cells could be more efficient in 
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prevention of cancer progression into other 
tissues. In addition, improvement of 
antisense oligonucleotides stability could 
increase their anti-invasive activity on 
prostate cancer cell lines. These antisense 
oligonucleotides could be examined in other 
cancer cell lines as well.  
 
5. Conclusion  
     According to the results obtained from 
this study, using twist1 specific antisense 
oligonucleotides can be a proper way for 
decreasing metastasis rate of prostate cancer 
cells in primary and also advanced stages. 
Discovering the potential role of these types 
of drugs for the treatment of various cancers 
has made new hopes for preventing cancer 
cells metastasis in patients. 
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